SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended: September 30, 1996 Commission File Number 0-27352

Hybridon, Inc.
(Exact name of registrant as specified in its charter)

Delaware	04-3072298
(State or other jurisdiction of organization or incorporation)	(I.R.S. Employer Identification Number)

One Innovation Drive
Worcester, Massachusetts 01605
(Address of principal executive offices, including zip code)

(508) 752-7000
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding as of October 31, 1996
Common Stock, par value $.001 per share	24,881,908

HYBRIDON, INC.

Form 10-Q

INDEX

HYBRIDON, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED CONDENSED BALANCE SHEETS

(UNAUDITED)

ASSETS

	SEPTEMBER 30, 1996	DECEMBER 31, 1995
CURRENT ASSETS:		
Cash and cash equivalents	$ 11,838,437	$ 5,284,262
Short-term investments	11,063,626	-
Prepaid expenses and other current assets	2,378,576	951,526
Total current assets	25,280,639	6,235,788
PROPERTY AND EQUIPMENT, AT COST:		
Laboratory equipment	7,216,985	5,153,550
Leasehold improvements	5,135,892	1,965,754
Equipment under capital leases	1,474,315	1,507,535
Office equipment	1,417,497	1,149,141
Furniture and fixtures	471,355	321,763
Construction-in-progress	5,194,548	3,236,330
	20,910,592	13,334,073
Less--Accumulated depreciation and amortization	5,828,623	4,202,543
	15,081,969	9,131,530
OTHER ASSETS:		
Restricted cash	658,602	1,025,856
Notes receivable from officers	315,504	308,133
Deferred financing costs and other assets	640,219	1,217,804
Deposit with real estate partnership	5,450,000	1,698,448
	7,064,325	4,250,241
	$ 47,426,933	$ 19,617,559

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:		
Current portion of long-term debt and capital lease obligations	$ 374,548	$ 418,713
Accounts payable	2,129,729	2,053,438
Accrued expenses	4,135,233	3,454,625
Deferred revenue	86,250	86,250
Amounts payable to related parties	34,000	12,500
Total current liabilities	6,759,760	6,025,526
LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS, NET OF CURRENT PORTION	837,796	1,145,480
MINORITY INTEREST	5,471,363	-
STOCKHOLDERS' EQUITY:		
Convertible preferred stock, $.01 par value-		
Authorized--none at September 30, 1996 and 23,026,323 shares at December 31, 1995		
Issued and outstanding--none at September 30, 1996 and 15,982,179 shares at December 31, 1995	-	159,822
Preferred stock, $.01 par value-		
Authorized--5,000,000 shares at September 30, 1996		
Issued and outstanding--None	-	-
Common stock, $.001 par value-		
Authorized--100,000,000 shares		
Issued and outstanding--24,823,908 shares at September 30, 1996 and 1,843,666 shares at December 31, 1995	24,824	1,844
Additional paid-in capital	169,132,210	114,626,062
Deficit accumulated during the development stage	(134,799,020)	(102,341,175)
Total stockholders' equity	34,358,014	12,446,553
	$ 47,426,933	$ 19,617,559

The accompanying notes are an integral part of these consolidated condensed financial statements.

HYBRIDON, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,		CUMULATIVE FROM MAY 25, 1989 (INCEPTION) TO SEPTEMBER 30,
	1996	1995	1996	1995	1996
REVENUES:					
Research and development	$ 358,750	$ 214,835	$ 1,076,250	$ 932,659	$ 4,211,124
Interest income	560,376	29,784	1,195,871	130,893	1,890,726
Royalty and other income	-	-	62,321	-	62,321
Product Revenue	611,520	-	611,520	-	611,520
	1,530,646	244,619	2,945,962	1,063,552	6,775,691
OPERATING EXPENSES:					
Research and development	10,242,296	5,604,484	27,326,434	20,026,847	106,567,809
General and administrative	2,766,429	1,591,798	7,989,722	4,638,090	33,432,920
Interest	18,070	44,591	87,651	134,893	1,573,982
	13,026,795	7,240,873	35,403,807	24,799,830	141,574,711
Net loss	$(11,496,149)	$(6,996,254)	$(32,457,845)	$(23,736,278)	$(134,799,020)
PRO FORMA NET LOSS PER COMMON SHARE (Note 2)	$ (.45)	$ (.43)	$ (1.35)	$ (1.56)	
SHARES USED IN COMPUTING PRO FORMA NET LOSS PER COMMON SHARE (Note 2)	25,732,987	16,120,812	23,989,439	15,249,146	

The accompanying notes are an integral part of these consolidated condensed financial statements.

HYBRIDON, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	NINE MONTHS ENDED SEPTEMBER 30,		CUMULATIVE FROM MAY 25, 1989 (INCEPTION) TO SEPTEMBER 30,
	1996	1995	1996
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net loss	$(32,457,845)	$(23,736,278)	$(134,799,020)
Adjustments to reconcile net loss to net cash used in operating activities-			
Depreciation and amortization	1,626,080	1,114,156	5,930,064
Compensation on grant of stock options, warrants and restricted stock	-	324,174	7,044,541
Amortization of discount on convertible promissory notes payable	-	-	690,157
Amortization of deferred financing costs	-	-	216,732
Noncash interest on convertible promissory notes payable	-	-	260,799
Changes in assets and liabilities-			
Prepaid and other current assets	(1,427,049)	25,874	(2,378,576)
Notes receivable from officers	(7,371)	42,376	(315,504)
Amounts payable to related parties	21,500	856,758	(166,000)
Accounts payable and accrued expenses	756,899	(981,207)	6,264,963
Deferred revenue	-	-	86,250
Net cash used in operating activities	(31,487,786)	(22,354,147)	(117,165,594)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Increase in short-term investments	(11,063,626)	-	(11,063,626)
Purchases of property and equipment, net	(7,576,520)	(3,211,844)	(20,476,241)
(Increase) decrease in restricted cash and other assets	418,118	(530,756)	(1,648,055)
Deposit with real estate partnership	(3,751,552)	-	(5,450,000)
Proceeds from sale/leaseback	-	-	1,073,183
Net cash used in investing activities	(21,973,580)	(3,742,600)	(37,564,739)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Proceeds from issuance of convertible preferred stock	-	35,979,873	96,584,154
Proceeds from issuance of common stock related to stock options and restricted stock grants	598,676	13,000	683,602
Proceeds from issuance of common stock related to stock warrants	1,539,386	-	1,539,386
Proceeds from sale of common stock	52,231,244	-	52,355,324
Repurchase of common stock	-	-	(263)
Proceeds from notes payable	-	-	1,950,000
Proceeds from issuance of convertible promissory notes payable	-	-	9,191,744
Proceeds from long-term debt	-	-	662,107
Payments on long-term debt and capital leases	(351,849)	(411,405)	(1,707,298)
Proceeds from sale of stock in subsidiary	5,471,363	-	5,471,363
Decrease (increase) in deferred financing costs	526,721	-	(161,349)
Net cash provided by financing activities	60,015,541	35,581,468	166,568,770
NET INCREASE IN CASH AND CASH EQUIVALENTS	6,554,175	9,484,721	11,838,437
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	5,284,262	3,395,783	-
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 11,838,437	$ 12,880,504	$ 11,838,437
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:			
Cash paid for interest	$ 87,651	$ 134,893	$ 534,325

The accompanying notes are an integral part of these consolidated condensed financial statements.

HYBRIDON, INC. AND SUBSIDIARIES
(A Development Stage Company)

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

(1) ORGANIZATION

Hybridon, Inc. (the Company) was incorporated in the State of Delaware on May 25, 1989. The Company is engaged in the discovery and development of novel genetic medicines based primarily on antisense technology.

The Company is in the development stage. Since inception, the Company has devoted substantially all of its efforts toward product research and development and raising capital. Management anticipates that substantially all future revenues will be derived from the sale of proprietary biopharmaceutical products under development or to be developed in the future, and contract manufacturing of synthetic DNA/RNA products and reagent products (manufactured by the Hybridon Specialty Products Division), as well as from research and development revenues and fees and royalties derived from licensing of the Company's technology. Accordingly, although the Company has begun to generate revenues from its contract manufacturing business, the Company is dependent on the proceeds from possible future sales of equity securities, debt financings and research and development collaborations in order to fund future operations.

The unaudited consolidated condensed financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission and include, in the opinion of management, all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of interim period results. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The Company believes, however, that its disclosures are adequate to make the information presented not misleading. The results for the interim periods presented are not necessarily indicative of results to be expected for the full fiscal year. It is suggested that these financial statements be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 1995, as filed with the Securities and Exchange Commission.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Pro Forma Net Loss per Common Share

Pro forma net loss per common share is computed using the weighted average number of shares of common stock outstanding during the period. Pursuant to the requirements of the Securities and Exchange Commission, common stock issued by the Company during the 12 months immediately preceding its initial public offering, plus shares of common stock that became issuable during the same period pursuant to the grant of common stock options and preferred and common stock warrants, has been included in the calculation of pro forma weighted average number of shares outstanding for the

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Pro Forma Net Loss per Common Share (Continued)

three and nine months ended September 30, 1995 and for the period from January 1, 1996 through February 2, 1996 (using the treasury-stock method and the initial public offering price of $10 per share). In addition, the calculation of the pro forma weighted average number of shares outstanding includes shares of common stock as if all shares of preferred stock were converted into common stock on the respective original dates of issuance.

RECLASSIFICATIONS

Certain amounts in the prior periods consolidated condensed financial statements have been reclassified to conform with the current periods presentation.

(3) CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

The Company applies SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities. Accordingly, the Company has classified its cash equivalents and short-term investments as held-to-maturity, and has recorded them at amortized cost, which approximates market value. Short-term investments mature within one year of the balance sheet date. Cash equivalents have original maturities of less than three months. Cash equivalents at September 30, 1996, includes approximately $5,900,000 held by MethylGene Inc., which is restricted to be used to fund MethylGene's operations and is not available to the Company, see Note 5. Cash and cash equivalents and short-term investments at September 30, 1996 and December 31, 1995 consisted of the following:

	SEPTEMBER 30, 1996	DECEMBER 31, 1995
Cash and Cash Equivalents-		
Cash and money market funds	$ 3,926,013	$5,284,262
U.S. government securities	7,912,424	-
	$11,838,437	$5,284,262
Short-term Investments-		
U.S. government securities	$11,063,626	$ -

(4) INITIAL PUBLIC OFFERING

On February 2, 1996, the Company completed its initial public offering of 5,750,000 shares of common stock at $10.00 per share. The sale of common stock resulted in net proceeds to the Company of approximately $52,231,000 after deducting expenses related to the offering. In addition, all outstanding shares of preferred stock were converted into 16,856,649 shares of common stock upon the consummation of the initial public offering.

(5) INVESTMENT IN METHYLGENE, INC.

In January 1996, the Company and certain institutional Canadian investors formed a Quebec company, MethylGene, Inc. (MethylGene), to develop and market certain compounds to be agreed upon by the Company and MethylGene.

The Company acquired a 49% interest in MethylGene for approximately $734,000, and the Canadian investors acquired a 51% interest in MethylGene for a total of approximately $5,500,000. MethylGene is a consolidated subsidiary of the Company and as a result, the cash held by MethylGene as of September 30, 1996 in the amount of approximately $5,900,000 is reflected in the consolidated condensed balance sheet and MethylGene's loss of approximately $135,000 for the nine months ended September 30, 1996 is reflected in the consolidated condensed statements of operations. The Company has recorded a minority interest liability as of September 30, 1996 for the net amount of proceeds received from such investors and expects to maintain a liability that reflects the option of the MethylGene investors to require the Company to exchange the investors' MethylGene stock for Hybridon stock (see below).

The Canadian investors have the right to exchange all (but not less than all) of their shares of stock in MethylGene for an aggregate of 500,000 shares of Hybridon common stock (subject to adjustment for stock splits, stock dividends and the like). This option is exercisable only during a 90-day period commencing on the earlier of the date five years after the closing of the institutional investors' investment in MethylGene or the date on which MethylGene ceases operations. This option terminates sooner if MethylGene raises certain additional amounts of equity or debt financing or if MethylGene enters into a corporate collaboration that meets certain requirements.

The Company has granted to MethylGene exclusive worldwide licenses and sublicenses in respect of certain technology relating to the MethylGene fields. In addition, the Company and MethylGene have entered into a supply agreement pursuant to which MethylGene is obligated to purchase from the Company all required formulated bulk oligonucleotides at specified transfer prices.

(6) CAMBRIDGE LEASE

The Company has entered into an amendment to the lease for its Cambridge facility pursuant to which, among other things, the Company has elected to treat $5,450,000 of its payments for a portion of the costs of the construction of the leased premises (primarily relating to tenant improvements) as contributions to the capital of the Cambridge landlord in exchange for a limited partnership interest in the Cambridge landlord (the Partnership Interest). The Company has the right, for a period of three years following completion of the building, to sell the Partnership Interest back to certain limited partners of the Cambridge landlord for a price equal to the greater of (i) the total $5,450,000 paid for the Partnership Interest or (ii) the fair market value of the Partnership Interest at the time. The assets of these limited partners are limited to their investment in the Cambridge landlord. The Cambridge landlord is an affiliate of three directors of the Company.

(7) WARRANTS

During the third quarter of 1996, the Company agreed with the holders of warrants to purchase 1,270,214 shares of common stock to correct an error in the expiration date of certain warrants by extending the expiration date from July 7, 1996 to October 25, 1996. During the third quarter of 1996 192,767 warrants for common stock were exercised with exercise prices of between $5.50 and $8.00 per share for total proceeds of $1,539,000. In October 1996, 204,669 warrants for common stock at an exercise price of $8.00 per share were exercised for total proceeds of $1,637,000 while 873,878 warrants were not exercised and expired in accordance with their terms.

(8) SUBSEQUENT EVENTS

Financing of Facility and Equipment

In November 1996, the Company entered into a non-binding letter of intent relating to a five-year $7,500,000 credit facility with a bank to finance the leasehold improvements of the Milford facility. The credit facility would be secured by a lien on all of the Company's assets and contains various covenants, including with respect to the liquidity of the Company and the Company's tangible net worth. The closing of the credit facility is subject to completion of due diligence and negotiation and execution of definitive documentation. There can be no assurance that the credit facility described in the letter of intent will be consummated.

In October 1996, the Company received a commitment letter relating to a $2,800,000 lease line with a leasing firm to finance the manufacturing equipment and other equipment in the Milford facility. The closing of this lease line is subject to negotiation and execution of definitive documentation. There can be no assurance that the lease line described in the commitment letter will be consummated.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Company is engaged in the discovery and development of genetic medicines based primarily on antisense technology. The Company commenced operations in February 1990 and since that time has been engaged primarily in research and development efforts, development of its manufacturing capabilities and organizational efforts, including recruitment of scientific and management personnel and raising capital. To date, the Company has not received revenue from the sale of biopharmaceutical products based on antisense technology although during the quarter ended September 30, 1996 the Company began contract manufacturing of synthetic DNA/RNA and reagent products manufactured by the

Hybridon Specialty Products Division in it's Milford facility. The Company anticipates increasing sales of these products. In order to commercialize the biopharmaceutical products, the Company will need to address a number of technological challenges and comply with comprehensive regulatory requirements. Accordingly, it is not possible to predict the amount of funds that will be required or the length of time that will pass before the Company receives revenues from sales of any of these products. The Company has generated revenue from collaborative agreements, interest on invested funds, and sales of synthetic DNA/RNA and reagent products produced by the Hybridon Specialty Products Division.

The Company has incurred losses since its inception and expects to incur significant operating losses in the future. The Company expects that its research and development expenses will increase significantly during the fourth quarter of 1996 and future years as it moves its principal research and development programs to more advanced preclinical studies, into clinical trials and to later phase clinical trials. In addition, the Company expects that its personnel and patent costs will significantly increase in the future. Costs associated with the Company's patent applications are expected to increase as the Company continues to file and prosecute such applications. Patent costs also would significantly increase if the Company became involved in litigation or administrative proceedings involving its patents or those of third parties. The Company has incurred cumulative losses since inception through September 30, 1996 of $134,800,000.

This Quarterly Report on Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are the factors set forth in the Company's Annual Report on Form 10-K under the caption Management's Discussion and Analysis of Financial Condition and Results of Operation--Certain Factors That May Affect Future Results, which are incorporated by reference herein. In addition, demand for and margins on the synthetic DNA/RNA and reagent products produced by the Hybridon Specialty Products Division may be lower than anticipated.

RESULTS OF OPERATIONS

Three and Nine Months Ended September 30, 1996 and 1995

The Company had total revenues of $1,531,000 and $245,000 in the three months ended September 30, 1996 and 1995, respectively, and $2,946,000 and $1,064,000 in the nine months ended September 30, 1996 and 1995, respectively. Revenues from research and development collaborations were $359,000 and $215,000 for the three months ended September 30, 1996 and 1995, respectively, and $1,076,000 and $933,000 for the nine month periods ended September 30, 1996 and 1995, respectively. Revenues for both the three month and nine month periods ended September 30 1996 and 1995 consisted of payments earned under a collaborative agreement with F. Hoffmann-La Roche Ltd (Roche). For the three month and nine month periods ended September 30, 1996, revenues also included payments under a collaborative agreement with G. D. Searle & Co. (Searle). Revenues from the Hybridon specialty products division were $612,000 for the three and nine month period ended September 30, 1996. Revenues from interest income were $560,000 and $30,000 for the three months ended September 30, 1996 and 1995, respectively, and $1,196,000 and $131,000 for the nine months ended September 30, 1996 and 1995, respectively. The increase in interest

income in both periods of 1996 was the result of substantially higher cash balances available for investment as a result of the Company's initial public offering completed on February 2, 1996.

The Company had research and development expenses of $10,242,000 and 5,605,000 in the three months ended September 30, 1996 and 1995, respectively, and $27,326,000 and $20,027,000 in the nine months ended September 30, 1996 and 1995, respectively. The increase in research and development expenses in the

three and nine months ended September 30, 1996 reflects increased expenses associated with salaries and related costs, facilities equipment costs related to additional laboratories, consulting and professional expense, expenses related to the production of GEM(R) 91 (an antisense oligonucleotide targeted at AIDS), and expenses for preclinical compounds. Research and development staffing and related costs increased significantly as the number of employees engaged in research and development activities increased by approximately 15 % in each of the three and nine month periods ending September 30, 1996. The Company expects to invest significant resources during the remainder of 1996 and future years in connection with the ongoing clinical trials of GEM(R) 91 and GEM(R) 132 (an antisense oligonucleotide targeted at cytomegalovirus), the performance of preclinical studies, and the preparation of IND applications with respect to additional antisense compounds.

The Company had general and administrative expenses of $2,767,000 and $1,592,000 in the three months ended September 30, 1996 and 1995, respectively, and $7,990,000 and $4,638,000 in the nine months ended September 30, 1996 and 1995, respectively. The increase in general and administrative expenses in the three and nine months ended September 30, 1996 was attributable primarily to an increase in legal and patent expenses, travel-related expenses, and salaries and related.

The Company had interest expense of $18,000 and $44,000 in the three months ended September 30, 1996 and 1995, respectively, and $88,000 and $135,000 in the nine months ended September 30, 1996 and 1995, respectively. Interest expense in the three and nine months ended September 30, 1996 and 1995 primarily consisted of interest incurred on borrowings to finance the purchase of property and equipment, and leasehold improvements. The decrease in interest expense in the three and nine months ended September 30, 1996 reflected a decrease in the debt outstanding during 1996.

As a result of the above factors, the Company incurred net losses of $11,496,000 and $6,996,000 for the three months ended September 30, 1996 and 1995, respectively, and $32,458,000 and $23,736,000 for the nine months ended September 30, 1996 and 1995, respectively.

LIQUIDITY AND CAPITAL RESOURCES

During the nine months ended September 30, 1996, the Company's net cash used in operating activity was $31,488,000 principally in connection with the Company's ongoing research and development programs. The Company also increased its investment in property and equipment by $7,688,000, consisting primarily of costs associated with the buildout of the Milford manufacturing facility and costs associated with leasehold improvements to the Cambridge facility. The Company's cash equivalents balance at September 30, 1996 includes $5,900,000 held by MethylGene Inc., a subsidiary of the Company, which amount is restricted to be used to fund MethylGene's operations and is not available to the Company. On February 2, 1996, the Company completed its initial public offering of common stock, which resulted in net proceeds to the Company of $52,231,000. As of September 30, 1996, the Company had invested $11,064,000 of the initial public offering proceeds in short term investments. As a result of the closing of the Company's initial public offering, all of the Company's previously outstanding series of convertible preferred stock were automatically converted into common stock.

The Company has signed a lease for a facility in Cambridge, Massachusetts, and expects to move its primary operations to such facility in the first quarter of 1997. The Company expects to incur significant costs in equipping and building out this facility, and the Company's facility costs will significantly increase when it takes occupancy of the Cambridge facility. The Company has entered into an amendment to the lease for its Cambridge facility pursuant to which, among other things, the Company has elected to treat $5,450,000 of its construction payments (primarily related to tenant improvements) as contributions to the capital of the Cambridge landlord in exchange for a limited partnership interest

in the Cambridge landlord. All other expenses in equipping and building of the facility in excess of the $5,450,000 are not exchangeable for a partnership interest under the lease amendment. The Cambridge landlord is an affiliate of three directors of the Company.

The Company expects that its capital requirements will increase in the future depending on numerous factors, including but not limited to the progress of the Company's research and development activities; the results and costs of preclinical studies and clinical trials; the timing and costs involved in obtaining regulatory approvals; the costs involved with filing, prosecuting, enforcing and defending patent claims; the costs associated with potential commercialization of products under development, including the development of manufacturing, marketing and sales capabilities; the ability of the Company to enter into additional collaborative arrangements; and the ability of the Company to obtain third-party financing for leasehold improvements and other capital expenditures.

The Hybridon Specialty Products Division of the Company generated revenues of $612,000 in the third quarter of 1996 and had an additional $700,000 of confirmed orders as of September 30, 1996.

During the third quarter of 1996, the Company agreed with the holders of warrants to purchase 1,270,214 shares of common stock to correct an error in the expiration date of certain warrants by extending the expiration date from July 7, 1996 to October 25, 1996. During the third quarter of 1996 192,767 warrants for common stock were exercised with exercise prices of between $5.50 and $8.00 per share for total proceeds of $1,539,000. In October 1996, 204,669 warrants for common stock at an exercise price of $8.00 per share were exercised for total proceeds of $1,637,000 while 873,878 warrants were not exercised and expired in accordance with the terms.

During the nine months ended September 30, 1996 the Company received $599,000 in proceeds from the issuance of common stock related to stock options.

In the third quarter of 1996, Roche notified the Company that, pursuant to the Company's research and development collaboration with Roche, Roche had selected an antisense oligonucleotide directed at human papilloma virus as a lead compound for further development. The selection of this oligonucleotide as a lead compound entitles the Company to a milestone payment from Roche, which the Company expects to receive in the fourth quarter of 1996. Roche also notified the Company in the third quarter of 1996 that Roche had elected not to continue the hepatitis B program under the research and development collaboration. In light of the prior selection by Roche of an antisense oligonucleotide directed at hepatitis C (the third program covered by the collaboration) as a lead compound, Roche notified the Company that Roche was exercising its option to terminate the research and development phase of the collaboration as of March 31, 1997. The Company and Roche are engaged in ongoing discussions as to the manner in which they will collaborate in connection with the further development of the two antisense oligonucleotides that have been selected by Roche as lead compounds.

In November 1996, the Company entered into a non-binding letter of intent relating to a five-year $7,500,000 credit facility with a bank to finance the leasehold improvements of the Milford facility. The credit facility would be secured by a lien on all of the Company's assets and contains various covenants, including liquidity of the Company and the Company's tangible net worth. The closing of the credit facility is subject to completion of due diligence and negotiation and execution of definitive documentation. There can be no assurance that the credit facility described in the letter of intent will be consummated.

In October 1996, the Company received a commitment letter relating to a $2,800,000 lease line with a leasing firm to finance the manufacturing equipment and other equipment in the Milford facility. The closing of this lease line is subject to negotiation and execution of definitive documentation. There can be no assurance that the lease line described in the commitment letter will be consummated.

Based on the anticipated funds to be received under the credit facility, and the lease line, as well as the expected revenues and margins from the contract manufacturing of synthetic DNA/RNA and reagent products by the Hybridon Specialty Products Division, the Company anticipates that its existing capital resources will be adequate to satisfy its capital requirements into the first quarter of 1997. The Company will require substantial additional funds from external sources in the first quarter of 1997 to support the Company's operations beyond that time.

The Company intends to seek additional equity, debt and lease financing to fund future operations, depending on the terms on which such sources of funding may be available from time to time. The Company also intends to seek additional collaborative development and commercialization relationships with potential corporate partners in order to fund certain of its programs. Except for research and development funding from Roche (which is scheduled to terminate on March 31, 1997) and Searle (which is subject to early termination in certain circumstances), Hybridon has no committed external sources of capital, and as discussed above, expects no revenues from the sale of biopharmaceutical products based on antisense technology for a number of years.

If the Company is unable to obtain necessary additional funds, it would be required to scale back or eliminate certain of its research and development programs, commercialization efforts or license to third parties certain technologies which the Company would otherwise pursue on its own.

HYBRIDON, INC.

PART II

OTHER INFORMATION

Item 1-5 None

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

11	Computation of Pro Forma Net Loss Per Common Share.
27	Financial Data Schedule (EDGAR)
99	Pages 36-39 of the Company's Annual Report on Form 10-K for the period ended December 31, 1995 (which is not deemed to be filed except to the extent that portions thereof are expressly incorporated by reference herein).

(b) No reports were filed on Form 8-K during the three months ended September 30, 1996.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HYBRIDON, INC.

November 13, 1996
Date

/s/ E. Andrews Grinstead III
E. Andrews Grinstead, III
Chairman, President and Chief Executive Officer (Principal Executive Officer)

November 13, 1996
Date

/s/ Anthony J. Payne
Anthony J. Payne
Senior Vice President of Finance and Administration and Chief Financial Officer (Principal Financial and Accounting Officer)

HYBRIDON, INC.

EXHIBIT INDEX

---

11 Computation of Pro Forma Net Loss Per Common Share.

27 Financial Data Schedule (EDGAR)

99 Pages 36-39 of the Company's Annual Report on Form 10-K for the period ended December 31, 1995 (which is not deemed to be filed except to the extent that portions thereof are expressly incorporated by reference herein).

EXHIBIT 11

HYBRIDON, INC. AND SUBSIDIARIES
(A Development Stage Company)

COMPUTATION OF PRO FORMA NET LOSS PER COMMON SHARE (1)

	THREE MONTHS ENDED SEPTEMBER 30,		NINE MONTHS ENDED SEPTEMBER 30,	
	1996	1995	1996	1995
NET LOSS	$(11,496,149)	$(6,996,254)	$(32,457,845)	$(23,736,278)
WEIGHTED AVERAGE COMMON AND COMMON EQUIVALENT SHARES:				
Weighted average common stock outstanding during the period	$ 25,732,987	$ 1,823,964	$ 22,085,644	$ 1,817,536
Conversion of preferred stock	--	13,773,264	1,845,619	12,908,026
Dilutive effect of common equivalent shares issued subsequent to October 31, 1994 (2)	--	523,584	58,176	523,584
	$ 25,732,987	$16,120,812	$ 23,989,439	$ 15,249,146
PRO FORMA NET LOSS PER COMMON SHARE	$ (.45)	$ (.43)	$ (.1.35)	$ (1.56)

<FN>
(1) Primary and fully diluted net loss per share has not been separately presented, as the amounts would not be meaningful.

(2) Pursuant to Securities and Exchange Commission Staff Accounting Bulletin No. 83, stock options issued at prices below the initial public offering price per share (cheap stock) during the 12-month period immediately preceding the initial filing date of the Company's Registration Statement of its initial public offering have been included as outstanding for all periods presented. The dilutive effect

of the common and common stock equivalents was computed in accordance with the treasury stock method.

<ARTICLE> 5
<CURRENCY> U.S. DOLLARS

<PERIOD-TYPE>	9-MOS
<FISCAL-YEAR-END>	DEC-31-1996
<PERIOD-START>	JAN-01-1996
<PERIOD-END>	SEP-30-1996
<EXCHANGE-RATE>	1
<CASH>	3,926,013
<SECURITIES>	18,976,050
<RECEIVABLES>	0
<ALLOWANCES>	0
<INVENTORY>	0
<CURRENT-ASSETS>	25,280,639
<PP&E>	20,910,592
<DEPRECIATION>	5,828,623
<TOTAL-ASSETS>	47,426,933
<CURRENT-LIABILITIES>	6,759,760
<BONDS>	837,796
<COMMON>	24,824
<PREFERRED-MANDATORY>	0
<PREFERRED>	0
<OTHER-SE>	34,333,190
<TOTAL-LIABILITY-AND-EQUITY>	47,426,933
<SALES>	611,520
<TOTAL-REVENUES>	2,945,962
<CGS>	0
<TOTAL-COSTS>	0
<OTHER-EXPENSES>	35,316,156
<LOSS-PROVISION>	0
<INTEREST-EXPENSE>	87,651
<INCOME-PRETAX>	(32,457,845)
<INCOME-TAX>	0
<INCOME-CONTINUING>	(32,457,845)
<DISCONTINUED>	0
<EXTRAORDINARY>	0
<CHANGES>	0
<NET-INCOME>	(32,457,845)
<EPS-PRIMARY>	(1.35)
<EPS-DILUTED>	(1.35)

EXHIBIT 99

Certain Factors That May Affect Future Results

The following important factors, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this Annual Report on Form 10-K and presented elsewhere by management from time to time.

Early Stage of Development; Technological Uncertainty

Hybridon's potential products are at an early stage of development. All of the Company's potential products are in research or development. There are a number of technological challenges that the Company must successfully address to complete any of its development efforts. To date, most of the Company's resources have been dedicated to applying oligonucleotide chemistry and cell biology to the research and development of potential pharmaceutical products based upon antisense technology. As in most drug discovery programs, the results of in vitro, tissue culture and preclinical studies by the Company may be inconclusive and may not be indicative of results that will be obtained in human clinical trials. In addition, results attained in early human clinical trials by the Company may not be indicative of results that will be obtained in later clinical trials. Neither the Company, nor to its knowledge, any other company has successfully completed human clinical trials of a product based on antisense technology, and there can be no assurance that any of the Company's products will be successfully developed.

Uncertainty Associated with Clinical Trials

Before obtaining regulatory approvals for the commercial sale of any of its products under development, the Company must undertake extensive and costly preclinical studies and clinical trials to demonstrate that such products are safe and efficacious. The results from preclinical studies and early clinical trials are not necessarily predictive of results that will be obtained in later stages of testing or development, and there can be no assurance that the Company's clinical trials will demonstrate the safety and efficacy of any products or will result in products capable of being produced in commercial quantities at reasonable cost or in a marketable form.

Although the Company is developing several oligonucleotide compounds on which it plans to file IND applications with the FDA and equivalent filings outside of the U.S., there can be no assurance that necessary preclinical studies on these compounds will be completed satisfactorily or that the Company otherwise will be able to make its intended filings. Further, there can be no assurance that the Company will be permitted to undertake and complete human clinical trials of any of the Company's potential products, either in the U.S. or elsewhere, or, if permitted, that such products will not have undesirable side effects or other characteristics that may prevent or limit their commercial use.

Future Capital Needs; Uncertainty of Additional Funding

The Company's future capital requirements will depend on many factors, including continued scientific progress in its research, drug discovery and development programs, the magnitude of these programs, progress with preclinical and clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting and enforcing patent claims, competing technological and market developments, the ability of the Company to establish and maintain collaborative academic and commercial research, development and marketing relationships, and the costs of

manufacturing scale-up and commercialization activities and arrangements.

Based upon its current operating plan, the Company anticipates that its existing capital resources will be adequate to satisfy its capital requirements for at least 12 months. The Company anticipates that it will be required to raise substantial

additional funds, including through collaborative relationships and public or private financings. No assurance can be given that additional financing will be available, or, if available, that it will be available on acceptable terms. If adequate funds are not available, the Company may be required to curtail significantly one or more of its research, drug discovery or development programs, or obtain funds through arrangements with collaborative partners or others that may require the Company to relinquish rights to certain of its technologies, product candidates or products which the Company would otherwise pursue on its own. See "Item 1. Business -- Hybridon Drug Development and Discovery Programs" and "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations -- Liquidity and Capital Resources."

History of Operating Losses and Accumulated Deficit

Hybridon has incurred net losses since its inception. At December 31, 1995, the Company's accumulated deficit was approximately $102,341,000. Such losses have resulted principally from costs incurred in the Company's research and development programs and from general and administrative costs associated with the Company's development. No revenues have been generated from product sales, and no product sales revenues are anticipated for a number of years, if ever. The Company expects to incur additional operating losses over the next several years and expects cumulative losses to increase significantly as the Company's research and development and clinical trial efforts expand. See "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations."

Patents and Proprietary Rights

The Company's success will depend in part on its ability to develop patentable products and obtain and enforce patent protection for its products both in the U.S. and in other countries. The Company has filed and intends to file applications as appropriate for patents covering both its products and processes. However, the patent positions of pharmaceutical and biotechnology firms, including Hybridon, are generally uncertain and involve complex legal and factual questions. No assurance can be given that patents will issue from any pending or future patent applications owned by or licensed to Hybridon or that the claims allowed under any issued patents will be sufficiently broad to protect the Company's technology.

The commercial success of the Company will also depend in part on its neither infringing patents issued to competitors or others nor breaching the technology licenses upon which the Company's products might be based. The Company's licenses of patents and patent applications impose various commercialization, sublicensing, insurance and other obligations on the Company. Failure of the Company to comply with these requirements could result in termination of the license. The Company is aware of patents and patent applications belonging to competitors, and it is uncertain whether these patents and patent applications will require the Company to alter its products or processes, pay licensing fees or cease certain activities. See "Item 1. Business - -- Patents, Trade Secrets and Licenses."

Need to Establish Collaborative Commercial Relationships; Dependence on Partners

Hybridon's business strategy includes entering into strategic alliances or licensing arrangements with corporate partners, primarily pharmaceutical and biotechnology companies, relating to the development and commercialization of

certain of its potential products. Although the Company is a party to corporate collaborations with Roche, Medtronic, Pharmacia and Searle, there can be no assurance that these collaborations will be scientifically or commercially successful, that the Company will be able to negotiate additional collaborations, that such collaborations will be available to the Company on acceptable terms or that any such relationships, if established, will be scientifically or commercially successful. See "Item 1. Business -- Hybridon Drug Development and Discovery Programs" and "-- Corporate Collaborations."

No Assurance of Regulatory Approval; Government Regulation

The Company's preclinical studies and clinical trials, as well as the manufacturing and marketing of its potential products, are subject to extensive regulation by numerous federal, state and local governmental authorities in the U.S. Similar regulatory requirements exist in other countries where the Company intends to test and market its drug candidates. Failure to

comply with applicable regulatory requirements can, among other things, result in fines, suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecutions. FDA policy may change and additional government regulations may be established that could prevent or delay regulatory approval of the Company's potential products. In addition, a marketed drug and its manufacturer are subject to continual review, and subsequent discovery of previously unknown problems with a product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market and withdrawal of the right to manufacture the product. All of the foregoing regulatory matters also will be applicable to development, manufacturing and marketing undertaken by any strategic partners or licensees of the Company. See "Item 1. Business -- Government Regulation."

Competition

There are many companies, both private and publicly traded, that are conducting research and development activities on technologies and products similar to or competitive with the Company's antisense technologies and proposed products. For example, many other companies are actively seeking to develop products, including antisense oligonucleotides, with disease targets similar to those being pursued by the Company. Some of these competitive products are in clinical trials. The Company believes that the industry-wide interest in investigating the potential of gene expression modulation technologies will continue and will accelerate as the techniques which permit the design and development of drugs based on such technologies become more widely understood. There can be no assurance that the Company's competitors will not succeed in developing products based on oligonucleotide or other technologies, existing or new, which are more effective than any that are being developed by the Company, or which would render Hybridon's antisense technologies obsolete and noncompetitive. Moreover, there currently are commercially available products for the treatment of certain of the disease targets being pursued by the Company.

Competitors of the Company engaged in all areas of biotechnology and drug discovery in the U.S. and other countries are numerous and include, among others, pharmaceutical and chemical companies, biotechnology firms, universities and other research institutions. Many of the Company's competitors have substantially greater financial, technical and human resources than the Company. In addition, many of these competitors have significantly greater experience than the Company in undertaking preclinical studies and human clinical trials of new pharmaceutical products and obtaining FDA and other regulatory approvals of products for use in health care. Furthermore, if the Company is permitted to commence commercial sales of products, it will also be competing with respect to manufacturing efficiency and marketing capabilities, areas in which it has limited or no experience. Accordingly, the Company's competitors may succeed in obtaining FDA or other regulatory approvals for products or in commercializing such products more rapidly than the Company. See "Item 1. Business --

Competition."

Limited Manufacturing Capability

While the Company believes that its existing production capacity and inventories of GEM 91 will be sufficient to enable it to satisfy its current research needs and its needs for clinical trials for this product candidate through 1996, and that its existing production capacity is sufficient to support the Company's other preclinical and clinical requirements for oligonucleotide compounds during such period, the Company will need to expand its manufacturing capacity in order to satisfy its future requirements for commercial production of GEM 91 and the Company's other product candidates. In addition, in order to successfully commercialize its product candidates, the Company may be required to reduce further the cost of production of its oligonucleotide compounds, and there can be no assurance that the Company will be able to do so.

The manufacture of the Company's products will be subject to GMP requirements prescribed by the FDA or other standards prescribed by the appropriate regulatory agency in the country of use. To the Company's knowledge, therapeutic products based on chemically-modified oligonucleotides have never been manufactured on a commercial scale. There can be no assurance that the Company will be able to manufacture or obtain products in a timely fashion and at acceptable quality and price levels, that it or its suppliers can manufacture in compliance with GMP or other regulatory requirements or that it or its suppliers will be able to manufacture an adequate supply of product. See "Item 1. Business -- Manufacturing."

Absence of Sales and Marketing Experience

The Company expects to market and sell certain of its products directly and through co-marketing or other licensing arrangements with third parties. There can be no assurance that the Company will be able to build such a marketing staff or sales force, that the cost of establishing such a marketing staff or sales force will be justifiable in light of any product revenues or that the Company's direct sales and marketing efforts will be successful. To the extent the Company enters into co-marketing or other licensing arrangements, any revenues received by the Company will be dependent in part on the efforts of third parties and there can be no assurance that such efforts will be successful. See "Item 1. Business -- Marketing Strategy."

Product Liability Exposure and Insurance

The use of any of the Company's potential products in clinical trials and the commercial sale of any products may expose the Company to liability claims. These claims might be made directly by consumers, health care providers or by pharmaceutical and biotechnology companies or others selling such products. Hybridon has limited product liability insurance coverage, and such coverage is subject to various deductibles. Such coverage is becoming increasingly expensive, and no assurance can be given that the Company will be able to maintain or obtain such insurance at reasonable cost or in sufficient amounts to protect the Company against losses due to liability claims that could have a material adverse effect on the Company.

Uncertainty of Health Care Reform Measures

Federal, state and local officials and legislators (and certain foreign government officials and legislators) have proposed or are reportedly considering proposing a variety of reforms to the health care systems in the U.S. and abroad. The Company cannot predict what health care reform legislation, if any, will be enacted in the U.S. or elsewhere. Significant changes in the health care system in the U.S. or elsewhere are likely to have a substantial impact over time on the manner in which the Company conducts its business. Such changes could have a material adverse effect on the Company. The existence of pending health care reform proposals could have a material adverse effect on the

Company's ability to raise capital.

Attraction and Retention of Key Employees and Scientific Collaborators

The Company's success is dependent on the retention of principal members of its management and scientific staff and on the recruitment of additional qualified scientific personnel who can provide additional expertise to the Company. The Company's success also depends in part on its continued ability to develop and maintain collaborative relationships with independent researchers and leading academic and research institutions. However, given the intense competition for experienced scientific personnel and for such collaborator relationships, there can be no assurance that the Company will be able to attract and retain scientific personnel or to develop and maintain collaborative agreements.